---
date created: 2024-11-18
tags:
  - meds
---
**Class:**
- Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

**Mechanism of Action (MOA):**
- Inhibits VMAT2, which reduces the uptake of monoamines into synaptic vesicles and decreases dopamine release, thereby helping to manage involuntary movements.

**Indications/Uses:**
- Treatment of tardive dyskinesia in adults

**Side Effects:**
- Somnolence
- Fatigue
- Dry mouth
- Headache
- Constipation

**Adverse Effects:**
- QT prolongation
- Potential for increased risk of depression or suicidal thoughts

**Nursing Teaching and Implications:**
- Monitor for signs of depression or changes in mood.
- Educate about the potential for drowsiness; advise caution when driving or operating machinery.
- Regularly monitor heart rhythm in patients at risk for QT prolongation.
- Encourage adherence to prescribed dosing schedule.

**Contraindications:**
- Known hypersensitivity to valbenazine
- Use with caution in patients with a history of cardiac arrhythmias